The Role of Hyperthermic Intraperitoneal Chemotherapy in Uterine Cancer Therapy
Authors:
- Iason PsilopatisIason Psilopatis
- Christos DamaskosChristos Damaskos
- Nikolaos GarmpisNikolaos Garmpis
- Kleio VrettouKVKleio Vrettou
- Anna GarmpiAGAnna Garmpi
- Panagiotis SarantisPanagiotis Sarantis
- Evangelos KoustasEvangelos Koustas
- Efstathios A. AntoniouEAEfstathios A. Antoniou
- Gregory KouraklisGKGregory Kouraklis
- Athanasios ChionisACAthanasios Chionis
- Konstantinos KontzoglouKKKonstantinos Kontzoglou
- Dimitrios DimitroulisDDDimitrios Dimitroulis
Open Access
- 2 August 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (15) , 12353
Abstract
Endometrial cancer and uterine sarcoma represent the two major types of uterine cancer. In advanced stages, both cancer entities are challenging to treat and correlate with a meagre survival and prognosis. Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is a form of localized chemotherapy that is heated to improve the chemotherapeutic effect on peritoneal metastases. The aim of the current review is to study the role of HIPEC in the treatment of uterine cancer. A literature review was conducted using the MEDLINE and LIVIVO databases with a view to identifying relevant studies. By employing the search terms “hyperthermic intraperitoneal chemotherapy”, “uterine cancer”, “endometrial cancer”, and/or “uterine sarcoma”, we managed to identify 26 studies published between 2004 and 2023. The present work embodies the most up-to-date, comprehensive review of the literature centering on the particular role of HIPEC as treatment modality for peritoneally metastasized uterine cancer. Patients treated with cytoreductive surgery, alongside HIPEC, seem to profit from not only higher survival but also lower recurrence rates. Factors such as the completeness of cytoreductive surgery, the peritoneal cancer index, the histologic subtype, or the applied chemotherapeutic agent, all influence HIPEC therapy effectiveness. In summary, HIPEC seems to represent a promising treatment alternative for aggressive uterine cancer.Keywords
This publication has 52 references indexed in Scilit:
- Debulking surgery and hyperthermic intraperitoneal chemotherapy in the management of a recurrent aggressive uterine myxoid leiomyosarcoma with peritoneal disseminationGynecologic Oncology Reports, 2015
- Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of recurrent high-grade uterine sarcoma with peritoneal disseminationAmerican Journal of Obstetrics and Gynecology, 2014
- Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for the treatment of endometrial cancer with peritoneal carcinomatosisEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2014
- Melphalan: A Promising Agent in Patients Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal ChemotherapyAnnals of Surgical Oncology, 2013
- Diagnosis and treatment of sarcoma of the uterus. A reviewActa Oncologica, 2012
- Peritoneal Sarcomatosis: Is There a Subset of Patients Who May Benefit from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy?Annals of Surgical Oncology, 2010
- Preclinical Studies of Chemotherapy Using Histone Deacetylase Inhibitors in Endometrial CancerObstetrics and Gynecology International, 2010
- Histone deacetylase inhibitors induce apoptosis in both Type I and Type II endometrial cancer cellsGynecologic Oncology, 2007
- Cytoreduction and intraperitoneal heated chemotherapy for the treatment of endometrial carcinoma recurrent within the peritoneal cavityInternational Journal of Gynecological Cancer, 2007
- p53 in endometrial cancer and its putative precursors: Evidence for diverse pathways of tumorigenesisHuman Pathology, 1995